BRIEF published on 01/30/2025 at 15:49, 1 year 7 months ago Divulgation de la participation du groupe Vanguard dans Direct Line Insurance Group Groupe Vanguard Code De Prise De Contrôle Vente D'actions Divulgation Des Enjeux Ligne Directe
PRESS RELEASE published on 01/30/2025 at 15:44, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.45% stake in Direct Line Insurance Group plc. Dealings include sale of ordinary shares Ordinary Shares Vanguard Group Stake Disclosure Dealings Direct Line Insurance
BRIEF published on 01/29/2025 at 15:46, 1 year 7 months ago Vanguard Group's Disclosure on Direct Line Insurance Group Securities Disclosure Takeover Code Vanguard Group Direct Line Insurance
BRIEF published on 01/29/2025 at 15:46, 1 year 7 months ago Divulgation du groupe Vanguard sur Direct Line Insurance Group Titres Groupe Vanguard Code De Prise De Contrôle Divulgation Assurance Ligne Directe
PRESS RELEASE published on 01/29/2025 at 15:41, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.45% interest in Direct Line Insurance Group plc as per Form 8.3 filing Securities Form 8.3 Disclosure The Vanguard Group Direct Line Insurance Group Plc
BRIEF published on 01/28/2025 at 15:29, 1 year 7 months ago Vanguard Group's 5.46% Stake in Direct Line Insurance Group Revealed Takeover Code Vanguard Group Stake Disclosure Stock Position Direct Line
BRIEF published on 01/28/2025 at 15:29, 1 year 7 months ago La participation de 5,46 % du groupe Vanguard dans Direct Line Insurance Group a été révélée Groupe Vanguard Code De Prise De Contrôle Divulgation Des Enjeux Position Des Stocks Ligne Directe
PRESS RELEASE published on 01/28/2025 at 15:24, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.46% interest in Direct Line Insurance Group plc. Additional disclosures in relation to Aviva plc Disclosure Vanguard Group Interests Direct Line Insurance Aviva Plc
BRIEF published on 01/27/2025 at 15:23, 1 year 7 months ago The Vanguard Group Discloses Position in Direct Line Insurance Group Regulatory Compliance Takeover Code Securities Disclosure Vanguard Group Direct Line
BRIEF published on 01/27/2025 at 15:23, 1 year 7 months ago Le groupe Vanguard révèle sa position dans Direct Line Insurance Group Groupe Vanguard Conformité Réglementaire Code De Prise De Contrôle Divulgation Des Valeurs Mobilières Ligne Directe
Published on 09/11/2026 at 04:00, 6 hours 50 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 12 hours 25 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 19 hours 30 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 19 hours 50 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 10:15, 35 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 1 hour 30 minutes ago Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 1 hour 45 minutes ago ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 1 hour 50 minutes ago Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 07:00, 3 hours 50 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 3 hours 50 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 3 hours 50 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 15 hours 20 minutes ago Availability of the 2026 Interim Financial Report
